Mariette X, et al. - This article was composed with the objective to describe lymphoma events in the tofacitinib rheumatoid arthritis (RA) clinical development program. The current study showed that the lymphoma rates were stable over time and minimal differences were seen in baseline characteristics of patients with and without lymphoma in the tofacitinib RA clinical development program.